Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

stada arzneimittel ag, bad vilbel array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

neuraxpharm bohemia s.r.o., praha array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 19410 fingolimod-hydrochlorid - tvrdá tobolka - 0,5mg - fingolimod

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

haleon czech republic s.r.o., praha array - 1064 paracetamol; 1122 fenylefrin-hydrochlorid; 102 kyselina askorbovÁ - prášek pro perorální roztok - 1000mg/10mg/70mg - paracetamol, kombinace kromĚ psycholeptik

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

haleon czech republic s.r.o., praha array - 15330 draselnÁ sŮl diklofenaku - obalená tableta - 25mg - diklofenak

Tsjekkia - tsjekkisk - SUKL (Státní ústav pro kontrolu léčiv)

haleon czech republic s.r.o., praha array - 15330 draselnÁ sŮl diklofenaku - měkká tobolka - 25mg - diklofenak

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

omrix biopharmaceuticals n. v. - lidský fibrinogen, lidský trombin - hemostáza - lokální hemostatika - podpůrná léčba v chirurgii dospělých, kde nejsou standardní chirurgické techniky dostatečné (viz bod 5). 1):- pro zlepšení hemostázy.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - imunopreparát pro felidae, - kočky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. následky imunitní odpovědi byly prokázány 1 týden po primárním očkování proti rhinotracheitidě, kaliciviru a chlamydophila felis. doba trvání imunity je 1 rok po poslední (opětovné) očkování.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - imunopreparát pro felidae, - kočky - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. nástup imunity byl prokázán jeden týden po primovakcinaci proti rhinotracheitidě, kalicivirové infekci chlamydophila felis a infekční panleukopenii komponenty. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Den europeiske union - tsjekkisk - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - imunopreparát pro felidae, - kočky - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.